Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro(Women & Infants Hospital of Rhode Island), Kathleen N. Moore(University of Oklahoma Medical Center), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), Charlie Gourley(Edinburgh Cancer Research), Michael Friedländer(Prince of Wales Hospital), Alexandra Léary(Institut Gustave Roussy), Giovanni Scambia(Agostino Gemelli University Polyclinic), William H. Bradley(Froedtert Hospital), Elizabeth Lowe(AstraZeneca (United States)), Gabe S. Sonke(Oncode Institute), Carol Aghajanian(Memorial Sloan Kettering Cancer Center), Byoung‐Gie Kim(Samsung Medical Center), Joyce F. Liu(Duke University), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ana Oaknin(Hebron University), Amit M. Oza(Ontario Institute for Cancer Research), Ralph Bloomfield(AstraZeneca (United Kingdom)), Anne Floquet(Institut Bergonié), Cara Mathews(Brown University), Nicoletta Colombo(University of Milano-Bicocca), Alla Lisyanskaya(City Clinical Oncology Center)
Cited by 122
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k